REST: Understanding Sleep Problems in Children With Autism Spectrum Disorder

Sponsor

Baylor College of Medicine (Other)

Overall Status

Completed

CT.gov ID

NCT00691080

Collaborator

Autism Speaks (Other), Oregon Health and Science University (Other), Columbia University (Other), The Emmes Company, LLC (Industry), Autism Treatment Network (Other)

Enrollment

Locations

Duration (Months)

19.3

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The investigators will examine whether sleep problems in children with autism spectrum disorder (ASD) are related to alterations in the production of melatonin (MT), a hormone that plays an important role in regulating sleep-wake cycle. Children with ASD experience high rates of sleep disturbances that potentially contribute to problems with thinking and behavior. It is unclear if changes in MT production cause sleep problems in children with ASD. MT is frequently used to treat these sleep problems; however, it has not been well established whether MT is an effective treatment. Our hypotheses concerning MT is children with ASD and sleep problems will have a delayed sleep-wake cycle and/or decreased MT production. This study will compare children diagnosed with ASD to "healthy" control children with no ASD diagnosis. All subjects will be recruited from one of three sites: Baylor College of Medicine, Oregon Health & Science University and Columbia University. The investigators will use a standardized questionnaire to determine whether the child has sleep problems. The investigators will measure MT levels in saliva in ASD children with sleep problems and in a group of control children without sleep problems. Total 24-hour MT production will be determined from urine samples in these same two groups.

Condition or Disease	Intervention/Treatment	Phase
Sleep Problems

Detailed Description

This is a proposal to study the relationship between melatonin (MT) and sleep problems in children with autism spectrum disorder (ASD), as part of the collaborative research structure of the Autism Treatment Network (ATN). A major goal of the ATN is to conduct clinical research that will have a significant impact on the daily lives and functioning of individuals with ASD and to address immediate concerns of parents. Children with ASD experience high rates of sleep disturbance, which likely contribute to the severity of their daytime cognitive and behavioral dysfunction and to poorer quality of life for them and their families.

As a step toward addressing sleep problems in ASD, we propose to test the hypothesis that children with ASD and sleep problems will have a delay in MT onset and/or have decreased MT secretion over 24 hours compared to normal controls.

Primary endpoint: Characterize the endogenous MT profiles in children with ASD:

We predict that results from this study will reveal lower levels of metabolized MT in children with ASD when compared to normal children. In addition, we anticipate that children with ASD will have delayed MT onset or altered circadian phase.

Data from this study will provide important information concerning circadian rhythm dysregulation in ASD and will support the development of future studies using MT to modify and correct abnormal circadian rhythms.

Study Design

Study Type:

Observational

Actual Enrollment :

58 participants

Observational Model:

Case-Control

Time Perspective:

Cross-Sectional

Official Title:

Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.

Study Start Date :

Sep 1, 2007

Actual Primary Completion Date :

Sep 1, 2011

Actual Study Completion Date :

Nov 1, 2011

Arms and Interventions

Arm	Intervention/Treatment
ASD children ASD children as defined by: Age greater than or equal to 4 or less than or equal to 9 years Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects). No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.) No current or use within the last 1 month of beta-blockers or melatonin No current use of sleep aids No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD) (6) No blindness.
"Healthy" control children "Healthy" control children as defined by: Age greater than or equal to 4 or less than or equal to 9 years A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children. No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.) No current or use within the last 1 month of beta-blockers or melatonin No current use of sleep aids; No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD) (6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions. (8) No sibling with a diagnosis of Autism Spectrum Disorder.

Arm

Intervention/Treatment

ASD children

ASD children as defined by: Age greater than or equal to 4 or less than or equal to 9 years Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects). No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.) No current or use within the last 1 month of beta-blockers or melatonin No current use of sleep aids No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD) (6) No blindness.

"Healthy" control children

"Healthy" control children as defined by: Age greater than or equal to 4 or less than or equal to 9 years A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children. No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.) No current or use within the last 1 month of beta-blockers or melatonin No current use of sleep aids; No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD) (6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions. (8) No sibling with a diagnosis of Autism Spectrum Disorder.

Outcome Measures

Primary Outcome Measures

Sleep Latency, as measured by actigraphy [1 week]

Secondary Outcome Measures

Total sleep time, as measured by actigraphy [1 week]

Eligibility Criteria

Criteria

Ages Eligible for Study:

4 Years to 9 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).
Age greater than or equal to 4 or less than or equal to 9 years;
Parents have given informed consent.
Parent/Caregiver fluent in written and spoken English.
Controls only: A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.

Exclusion Criteria:

Current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)*;
Current or use within the last 1 month of beta-blockers or melatonin;
Current use of sleep aids;
Presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD);
Blindness.
Controls only: current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions. (7) Controls only: Sibling has a diagnosis of Autism Spectrum Disorder.

Psychoactive medications can be discontinued but the parents must discuss medication discontinuation with their prescribing physician prior to reducing or stopping the medications.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Columbia University	New York	New York	United States	10032
2	Oregon Health & Sciences University	Portland	Oregon	United States	97239
3	Baylor College of Medicine	Houston	Texas	United States	77030